CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer

• Published in: BMC gastroenterology 2023-08, Vol.23 (1), p.1-283, Article 283
• Main Authors: Wang, Canming, Wang, Yukai, Chen, Jinxia, Wang, Yi, Pang, Chuhong, Liang, Chen, Yuan, Li, Ma, Yubo
• Format: Article
• Language: English
• Subjects: Analysis; Antibodies; Cancer therapies; Care and treatment; CD4 antigen; CD8 antigen; Claudin 18.2; Cytotoxicity; Dosage and administration; ErbB-2 protein; Gastric cancer; Gastroenterology; Gene expression; Genetic aspects; Immune microenvironment; Immunohistochemistry; Immunotherapy; Lymph nodes; Lymphatic system; Lymphocytes; Lymphocytes T; Medical prognosis; Medical records; Metastases; Metastasis; Microenvironments; Monoclonal antibodies; Patients; PD-L1 protein; Permeability; Prevention; Prognosis; Risk factors; Stomach cancer; Tumors
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-023-02924-y

Background The investigational use of zolbetuximab (IMAB362), a groundbreaking monoclonal antibody medication targeting claudin 18.2 (CLDN18.2), for treatment of advanced gastrointestinal cancers is currently underway. The unclear clinicopathological characteristics and tumour immune microenvironment of CLDN18.2-positive gastric cancer (GC) make it difficult to develop and optimize CLDN18.2-targeted therapies. Methods A total of 451 tumour tissues, 342 matched paraneoplastic tissues, and 107 matched metastatic lymph nodes were collected from GC patients. These specimens were stained for CLDN18.2 expression and quantified using immunohistochemistry (IHC). Correlations between CLDN18.2 expression and clinicopathological features as well as immune-related factors were analysed. Survival curves were drawn using the Kaplan-Meier approach, and independent factors affecting GC prognosis were identified using Cox regression analysis. Information from relevant databases was used for corroboration. Results Expression of the CLDN18.2 gene was significantly lower in gastric tumour tissues than in normal tissues (p < 0.001) but comparable in metastatic lymph nodes (p = 0.851). CLDN18.2 expression was significantly associated with Borrmann type, degree of differentiation, PD-L1 expression, and survival in GC patients and was identified as an independent risk factor for patient prognosis (HR = 1.57, 95% CI 1.16-2.11, p = 0.003). There was no correlation between CLDN18.2 expression and HER2, Lauren type, tumour size, TNM stage, or any other clinicopathological characteristic. In CLDN18.2-positive tumours, fractions of CD4 + T cells and CD8 + T cells were significantly higher than those in CLDN18.2-negative tumours. Patients with CLDN18.2-negative expression and significant CD4 + T-cell or CD8 + T-cell infiltration had the best prognosis (5-year OS: 61.0%, P = 0.036; 5-year OS: 62.2%, P = 0.034). Conclusions CLDN18.2 is expressed at a low level in tumour tissues and serves as an independent prognostic factor for patients with GC. Furthermore, CLDN18.2 correlates with immune infiltrating cells and PD-L1 expression. Keywords: Claudin 18.2, Gastric cancer, Prognosis, Immune microenvironment